NCT03784898View on ClinicalTrials.gov

Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada

PHASE4CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

February 8, 2019

Primary Completion Date

December 11, 2019

Study Completion Date

December 11, 2019

Conditions
Multiple Sclerosis
Interventions
OTHER

Blood draw for future biomarker analysis

Each participant was required to undergo blood draw for future genetic testing and biomarker analysis as mentioned in the informed consent form (ICF).

Trial Locations (1)

90094

Investigational Site Number 8400001, Los Angeles

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT03784898 - Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada | Biotech Hunter | Biotech Hunter